Golden State Equity Partners Adicet Bio, Inc. Transaction History

Golden State Equity Partners

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 01, 2023	SELL	$5.52 - $9.23 $34,135 - $57,078	-6,184 Reduced 20.6%	23,830 $137 Million
Q1 2022 May 18, 2022	BUY	$11.53 - $19.97 $194,499 - $336,873	16,869 Added 128.33%	30,014 $599,000
Q1 2022 May 16, 2022	SELL	$11.53 - $19.97 $194,384 - $336,674	-16,859 Reduced 56.19%	13,145 $172,000
Q4 2021 Feb 11, 2022	BUY	$7.37 - $17.49 $5,159 - $12,242	700 Added 2.39%	30,004 $525,000
Q3 2021 Nov 15, 2021	BUY	$6.29 - $9.93 $96,268 - $151,978	15,305 Added 109.33%	29,304 $230,000
Q2 2021 Aug 12, 2021	BUY	$9.19 - $15.93 $7,848 - $13,604	854 Added 6.5%	13,999 $144,000
Q4 2020 Feb 08, 2021	BUY	$10.36 - $14.77 $136,182 - $194,151	13,145 New	13,145 $184,000

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $39.6M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

Stay updated on Golden State Equity Partners with notifications on news.